Author:
Hedman Katarina,Kordzakhia George,Li Hongjian,Nyström Per
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. US Food and Drug Administration, Draft Guidance for Industry. Meta-Analyses of randomized controlled clinical trials to evaluate the safety of human drugs or biological products. 2018; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meta-analyses-randomized-controlled-clinical-trials-evaluate-safety-human-drugs-or-biological
2. US Food and Drug Administration, Guidance for Industry. Premarketing risk assessment. 2005; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarketing-risk-assessment
3. Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials. 2009;6:430–40.
4. Berlin JA, Crowe BJ, Whalen E, et al. Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions. Clin Trials. 2013;10(1):20–31.
5. Simpson EH. The interpretation of interaction in contingency tables. J R Stat. 1951;13(2):238–41.